HB0034 vs Imsidolimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-36 receptor · full Psoriasis pipeline
HB0034
Developed by Shanghai Huaota Biopharmaceutical Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Imsidolimab
Developed by Vanda Pharmaceuticals under a licence from AnaptysBio
NCT05352893 · Phase 3 · completed
GEMINI-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 45 patients with a generalized pustular psoriasis flare, randomized 1:1:1 to a single IV dose of imsidolimab 750 mg, 300 mg or placebo. The primary endpoint was GPPPGA 0 or 1 (clear or almost clear) at week 4: 53.3% with 750 mg vs 13.3% with placebo (p=0.0131), so the primary was met. The 300 mg arm had the same response count (8 of 15) on CT.gov, but the release gives no test for it. Sources: CT.gov posted results and the AnaptysBio press release filed on SEC Form 8-K.
Reported efficacy
Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) (Week 4): GPPPGA 0/1 at week 4: imsidolimab 750 mg IV 53.3% (8/15) vs placebo 13.3% (2/15), p=0.0131; 300 mg IV 8/15 (CT.gov, no test posted for 300 mg) (AnaptysBio release, 9 Oct 2023, SEC 8-K). (met)
Result source: NCT05352893
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HB0034 | Imsidolimab |
|---|---|---|
| PASI 75 | —Not reported | —Not reported |
| PASI 90 | —Not reported | —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | —Not reported | —Not reported |
| DLQI, change | —Not reported | —Not reported |
PASI 75
- HB0034
- —Not reported
- Imsidolimab
- —Not reported
PASI 90
- HB0034
- —Not reported
- Imsidolimab
- —Not reported
PASI 100
- HB0034
- —Not reported
- Imsidolimab
- —Not reported
sPGA 0/1
- HB0034
- —Not reported
- Imsidolimab
- —Not reported
DLQI, change
- HB0034
- —Not reported
- Imsidolimab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HB0034: no structured comparison results are available for Psoriasis.
Imsidolimab: registry results are on file for Psoriasis, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0034's landscape · Imsidolimab's landscape